This lecture is about pharmacotherapy for obesity.
I'm Jeo Prieto.
I am Professor Emeritus at the University of Melbourne and
the head of the Byte Control Clinic at Austin Health in Melbourne.
I'm also chair of the Clinical Care Committee of World Obesity.
Before I start, I need to declare that I am currently chair
of the Medical Advisory Board for Liraglutide in Australia for Novo Nordisk.
I've also given lectures on Weight Management
for iNova who market phentermine in Australia.
Some years ago, in fact in 2003
the National Health and Medical Research Council in Australia
developed evidence-based guidelines for the management of obesity.
As part of that,
they've reviewed literature on various strategies for weight loss including: diets,
exercise and psychological treatments and investigated
the acute weight losses and then the two year outcomes of those weight loss strategies.
In this slide, you see the effects of diet therapies on the left-hand column.
You can see the types of diets that were found in the literature including;
low fat, low energy, very low energy,
meal replacements and there are different degrees of a fat losses from
3.9 which had low-fat diets to 11.8 with very low energy diets.
But the weight-loss at two years was less as most patients regained the weight.